Headquartered in Brisbane, CA Fiscal year ends November NASDAQ: NRIX nurixtx.com
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and autoimmune diseases. Its clinical-stage oncology pipeline includes bexobrutideg (NX-5948), a brain-penetrant degrader of Bruton's tyrosine kinase (BTK) being co-developed with Roche across malignant hematology, immunology, and neurology, and NX-1607, an oral inhibitor of CBL-B being evaluated across multiple solid tumor types. The company's autoimmune disease pipeline includes bexobrutideg and clinical-stage degraders of IRAK4 (in collaboration with Gilead) and STAT6 (in collaboration with Sanofi). Nurix maintains strategic collaborations with Roche, Gilead Sciences, Sanofi, and Pfizer, retaining certain options for co-development, co-commercialization, and profit sharing in the United States for multiple drug candidates. The company's AI-integrated discovery engine is designed to tackle virtually any protein class using its ligase expertise in targeted protein degradation. Updated
The Roche deal just flipped eight straight quarters of losses into net income of $549.8 million, removing the financing overhang ahead of the Phase 3 bexobrutideg readout. Recurring revenue is still tiny.
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and autoimmune diseases.
The Wall Street consensus 12-month price target for NRIX is $34.50.
